Table 2.
Compounds | ||||||
---|---|---|---|---|---|---|
GSK-1 | GSK-2 | GSK-3 | GSK-4 | GSK-5 | GSK-6 | |
Yeast HTS Growth Assay-GSK (μM) | 3.16 | 0.25 | 2.51 | 3.98 | 63.1 | 10 |
Yeast Kill Assay-GSK (μM) | 0.63 | <0.08 | 0.63 | 1.26 | 6.31 | 1.26 |
Yeast Kill Assay-Akabas lab (μM) | 0.54 ± 0.20 | 0.11 ± 0.04 | 0.46 ± 0.30 | 0.43 ± 0.30 | 4.0 ± 1.3 | 1.2 ± 1.1 |
PfENT1 [3H]Ado uptake (μM) | 0.12 ± 0.08 | 0.03 ± 0.03 | 0.03 ± 0.01 | 0.02 ± 0.01 | 2.59 ± 2.36 | 3.98 ± 1.35 |
PvENT1 [3H]Ado uptake (μM)b | 0.14 ± 0.07 | 0.04 ± 0.03 | 0.04 ± 0.01 | 0.02 ± 0.04 | 2.71 ± 0.25 | NEd |
PbENT1 [3H]Ado uptake (μM)c | 0.13 ± 0.05 | 0.05 ± 0.03 | 0.07 ± 0.04 | 0.01 ± 0.01 | 3.09 ± 2.70 | NEd |
3D7 (μM) | 0.78 ± 0.2 | 2.25 ± 0.4 | 2.38 ± 0.5 | 6.20 ± 1.9 | 8.72 ± 1.6 | 10.3 ± 4.7 |
PfENT1-KO (μM) | 17 ± 4.8 | 2.66 | Low activity/NEe | 29.4 ± 0.5 | 10.8 | NEe |
Dd2 (μM) | 0.11 ± 0.009 | 1.89 ± 0.2 | 0.59 ± 0.05 | 1.90 ± 0.4 | 10.6 ± 2.1 | 3.3 ± 1.7 |
HB3 (μM) | 0.34 ± 0.1 | 3.55 ± 0.7 | 2.21 ± 0.6 | 6.16 ± 2.5 | 9.09 ± 4.5 | 19.7 ± 4.1 |
7G8 (μM) | 0.48 ± 0.2 | 4.52 ± 0.1 | 6.08 ± 1.3 | 8.44 ± 2.4 | 16.1 ± 5.5 | 19.0 ± 3.5 |
Cam3.II Artemisinin resistant (μM) | 0.16 ± 0.09 | 1.37 ± 0.2 | 0.79 ± 0.2 | 3.02 ± 1.6 | 8.37 ± 1.4 | 6.07 ± 1.0 |
hENT1 [3H]adenosine uptake into RBC (μM) | 0.99 ± 0.81 | 24.5 ± 24.8 | 72.4 ± 19.3 | 51.0 ± 27.7 | Low activity/NEd | NEd |
hFNT [3H]hypoxanthine uptake into RBC (μM) | 0.38 ± 0.1 | NEd | 9.93 ± 4.1 | NEd | 3.54 ± 1.5 | NEd |
HepG2 cell cytotoxicity (μM)f | >100 | >100 | >100 | >100 | >100 | >100 |
Molecular weight | 475 | 402 | 363 | 341 | 254 | 338 |
Solubility (μg/mL) | 10.5 | 2.5 | 112 | 156 | 16 | >133 |
ChromLogDpH7.4g | 4.8 | 6.8 | 4 | 4.5 | 3.7 | 1.2 |
PFIh | 8.8 | 9.6 | 6 | 6.5 | 5.7 | 4.2 |
HSA Column bindingi | 94% | 97% | 84% | 92% | 90% | 48% |
Values are mean ± SD. N ≥ 3 for all experiments except for the “5-FUrd growth assay-GSK” and the “Ado dependent growth-GSK columns”, where N=2, and for the PfENT1-KO experiments with compounds GSK-2 and GSK-5, where N=1.
PvENT1, yeast expressing the P. vivax ENT1 homologue
PbENT1, yeast expressing the mouse malaria model P. berghei ENT1 homologue
NE, no effect at the maximum concentration tested, 100 μM. Low activity/NE, indicates that at the highest concentration tested there seemed to be an effect, but it was not sufficient to calculate an IC50 value.
NE, no effect at the maximum concentration tested, 74.2 μM. Low activity/NE, indicates that at the highest concentration tested there seemed to be an effect, but it was not sufficient to calculate an IC50 value.
For the HepG2 cell cytotoxicity data, and >100 indicates no cytotoxicity up to 100 μM.
HSA, human serum albumin.61